Do analysts prefer INKT or FTFT?

MiNK Therapeutics currently has a consensus price target of $35.00, indicating a potential upside of 183.86%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe MiNK Therapeutics is more favorable than Future FinTech Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.40 Future FinTech Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor INKT or FTFT?

In the previous week, MiNK Therapeutics and MiNK Therapeutics both had 1 articles in the media. MiNK Therapeutics' average media sentiment score of 0.00 equaled Future FinTech Group'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Future FinTech Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor INKT or TRDA?

In the previous week, Entrada Therapeutics had 1 more articles in the media than MiNK Therapeutics. MarketBeat recorded 2 mentions for Entrada Therapeutics and 1 mentions for MiNK Therapeutics. Entrada Therapeutics' average media sentiment score of 1.60 beat MiNK Therapeutics' score of 0.00 indicating that Entrada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Entrada Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher earnings & valuation, FBRX or INKT?

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Forte Biosciences N/A N/A -$69.38M -$4.64 N/A MiNK Therapeutics N/A N/A -$12.49M -$2.84 N/A

Is FBRX or INKT more profitable?

MiNK Therapeutics' return on equity of 0.00% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Forte Biosciences N/A -106.17% -85.50% MiNK Therapeutics N/A N/A -118.57%

Is HUMA or INKT more profitable?

MiNK Therapeutics has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. MiNK Therapeutics' return on equity of 0.00% beat Humacyte's return on equity. Company Net Margins Return on Equity Return on Assets Humacyte -4,836.06% -2,914.18% -89.45% MiNK Therapeutics N/A N/A -118.57%

MiNK Therapeutics (INKT) Competitors

$12.33 +0.08 (+0.65%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$12.00 -0.33 (-2.68%)

As of 08:39 AM Eastern

Compare

INKT vs. FTFT, TRDA, FBRX, AKBA, and HUMA

Should you buy MiNK Therapeutics stock or one of its competitors? MarketBeat compares MiNK Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MiNK Therapeutics include Future FinTech Group (FTFT), Entrada Therapeutics (TRDA), Forte Biosciences (FBRX), Akebia Therapeutics (AKBA), and Humacyte (HUMA).

How does MiNK Therapeutics compare to Future FinTech Group?

MiNK Therapeutics (NASDAQ:INKT) and Future FinTech Group (NASDAQ:FTFT) are related small-cap companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

MiNK Therapeutics has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, Future FinTech Group has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

In the previous week, MiNK Therapeutics and MiNK Therapeutics both had 1 articles in the media. MiNK Therapeutics' average media sentiment score of 0.00 equaled Future FinTech Group'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiNK Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Future FinTech Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiNK Therapeutics has a net margin of 0.00% compared to Future FinTech Group's net margin of -37.76%. MiNK Therapeutics' return on equity of 0.00% beat Future FinTech Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-118.57%
Future FinTech Group	-37.76%	-13.08%	-10.33%

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Future FinTech Group shares are held by institutional investors. 20.4% of MiNK Therapeutics shares are held by insiders. Comparatively, 1.5% of Future FinTech Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Future FinTech Group has higher revenue and earnings than MiNK Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Future FinTech Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A
Future FinTech Group	$3.83M	1.05	-$4.62M	-$3.17	N/A

MiNK Therapeutics currently has a consensus price target of $35.00, indicating a potential upside of 183.86%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe MiNK Therapeutics is more favorable than Future FinTech Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Future FinTech Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

MiNK Therapeutics beats Future FinTech Group on 9 of the 14 factors compared between the two stocks.

How does MiNK Therapeutics compare to Entrada Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

MiNK Therapeutics has higher earnings, but lower revenue than Entrada Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A
Entrada Therapeutics	$25.42M	11.06	-$143.75M	-$3.99	N/A

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 20.4% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

MiNK Therapeutics has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -2,895.05%. MiNK Therapeutics' return on equity of 0.00% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-118.57%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

MiNK Therapeutics currently has a consensus target price of $35.00, suggesting a potential upside of 183.86%. Entrada Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 141.71%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe MiNK Therapeutics is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

MiNK Therapeutics has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.26, suggesting that its share price is 126% less volatile than the broader market.

In the previous week, Entrada Therapeutics had 1 more articles in the media than MiNK Therapeutics. MarketBeat recorded 2 mentions for Entrada Therapeutics and 1 mentions for MiNK Therapeutics. Entrada Therapeutics' average media sentiment score of 1.60 beat MiNK Therapeutics' score of 0.00 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiNK Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Entrada Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

MiNK Therapeutics beats Entrada Therapeutics on 9 of the 16 factors compared between the two stocks.

How does MiNK Therapeutics compare to Forte Biosciences?

Forte Biosciences (NASDAQ:FBRX) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are held by institutional investors. 4.4% of Forte Biosciences shares are held by insiders. Comparatively, 20.4% of MiNK Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Forte Biosciences presently has a consensus target price of $67.00, suggesting a potential upside of 269.15%. MiNK Therapeutics has a consensus target price of $35.00, suggesting a potential upside of 183.86%. Given Forte Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Forte Biosciences is more favorable than MiNK Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
MiNK Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A

MiNK Therapeutics' return on equity of 0.00% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-106.17%	-85.50%
MiNK Therapeutics	N/A	N/A	-118.57%

Forte Biosciences has a beta of 2.87, suggesting that its stock price is 187% more volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market.

In the previous week, MiNK Therapeutics had 1 more articles in the media than Forte Biosciences. MarketBeat recorded 1 mentions for MiNK Therapeutics and 0 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 0.00 equaled MiNK Therapeutics'average media sentiment score.

Company	Overall Sentiment
Forte Biosciences	Neutral
MiNK Therapeutics	Neutral

Summary

Forte Biosciences beats MiNK Therapeutics on 7 of the 13 factors compared between the two stocks.

How does MiNK Therapeutics compare to Akebia Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

MiNK Therapeutics has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -8.83%. MiNK Therapeutics' return on equity of 0.00% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-118.57%
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

MiNK Therapeutics presently has a consensus price target of $35.00, indicating a potential upside of 183.86%. Akebia Therapeutics has a consensus price target of $4.67, indicating a potential upside of 324.24%. Given Akebia Therapeutics' higher possible upside, analysts clearly believe Akebia Therapeutics is more favorable than MiNK Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 20.4% of MiNK Therapeutics shares are owned by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Akebia Therapeutics has higher revenue and earnings than MiNK Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A
Akebia Therapeutics	$236.20M	1.25	-$5.34M	-$0.08	N/A

In the previous week, MiNK Therapeutics had 1 more articles in the media than Akebia Therapeutics. MarketBeat recorded 1 mentions for MiNK Therapeutics and 0 mentions for Akebia Therapeutics. MiNK Therapeutics' average media sentiment score of 0.00 equaled Akebia Therapeutics'average media sentiment score.

Company	Overall Sentiment
MiNK Therapeutics	Neutral
Akebia Therapeutics	Neutral

MiNK Therapeutics has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market.

Summary

MiNK Therapeutics beats Akebia Therapeutics on 8 of the 15 factors compared between the two stocks.

How does MiNK Therapeutics compare to Humacyte?

Humacyte (NASDAQ:HUMA) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

MiNK Therapeutics has lower revenue, but higher earnings than Humacyte. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.02M	77.13	-$40.83M	-$0.57	N/A
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A

In the previous week, Humacyte and Humacyte both had 1 articles in the media. MiNK Therapeutics' average media sentiment score of 0.00 beat Humacyte's score of -0.50 indicating that MiNK Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Humacyte	Negative
MiNK Therapeutics	Neutral

44.7% of Humacyte shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 3.1% of Humacyte shares are owned by insiders. Comparatively, 20.4% of MiNK Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Humacyte currently has a consensus target price of $6.25, suggesting a potential upside of 792.35%. MiNK Therapeutics has a consensus target price of $35.00, suggesting a potential upside of 183.86%. Given Humacyte's stronger consensus rating and higher possible upside, research analysts plainly believe Humacyte is more favorable than MiNK Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
MiNK Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

MiNK Therapeutics has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. MiNK Therapeutics' return on equity of 0.00% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,836.06%	-2,914.18%	-89.45%
MiNK Therapeutics	N/A	N/A	-118.57%

Humacyte has a beta of 2.45, meaning that its share price is 145% more volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market.

Summary

Humacyte beats MiNK Therapeutics on 9 of the 15 factors compared between the two stocks.

Get MiNK Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INKT vs. The Competition

Export

Metric	MiNK Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$61.43M	$3.45B	$6.44B	$12.30B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-4.34	19.75	24.66	23.99
Price / Sales	N/A	329.51	531.91	108.06
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	-4.07	8.29	10.81	6.50
Net Income	-$12.49M	$23.85M	$3.56B	$336.88M
7 Day Performance	0.98%	2.87%	0.93%	-0.16%
1 Month Performance	13.43%	2.19%	0.35%	0.76%
1 Year Performance	68.90%	55.48%	29.69%	28.49%

MiNK Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INKT MiNK Therapeutics	2.9041 of 5 stars	$12.33 +0.7%	$35.00 +183.9%	+64.8%	$61.43M	N/A	N/A	30	Gap Down
FTFT Future FinTech Group	0.5399 of 5 stars	$0.84 -8.8%	N/A	-83.7%	$5.43M	$3.83M	N/A	70	Positive News
TRDA Entrada Therapeutics	3.9976 of 5 stars	$6.46 +2.4%	$17.50 +170.9%	+2.8%	$244.96M	$25.42M	N/A	110	Positive News
FBRX Forte Biosciences	1.5501 of 5 stars	$17.56 +0.9%	$67.00 +281.5%	+42.2%	$241.61M	N/A	N/A	5	Gap Down
AKBA Akebia Therapeutics	1.491 of 5 stars	$0.92 +2.8%	$4.67 +404.8%	-69.8%	$241.27M	$236.20M	N/A	430

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INKT) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MiNK Therapeutics (INKT) Competitors

INKT vs. FTFT, TRDA, FBRX, AKBA, and HUMA

How does MiNK Therapeutics compare to Future FinTech Group?

Summary

How does MiNK Therapeutics compare to Entrada Therapeutics?

Summary

How does MiNK Therapeutics compare to Forte Biosciences?

Summary

How does MiNK Therapeutics compare to Akebia Therapeutics?

Summary

How does MiNK Therapeutics compare to Humacyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INKT vs. The Competition

MiNK Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MiNK Therapeutics (INKT) Competitors

INKT vs. FTFT, TRDA, FBRX, AKBA, and HUMA

How does MiNK Therapeutics compare to Future FinTech Group?

Which has more volatility & risk, INKT or FTFT?

Does the media favor INKT or FTFT?

Is INKT or FTFT more profitable?

Do insiders and institutionals believe in INKT or FTFT?

Which has stronger valuation and earnings, INKT or FTFT?

Do analysts prefer INKT or FTFT?

Summary

How does MiNK Therapeutics compare to Entrada Therapeutics?

Which has preferable earnings & valuation, INKT or TRDA?

Do insiders and institutionals hold more shares of INKT or TRDA?

Is INKT or TRDA more profitable?

Do analysts prefer INKT or TRDA?

Which has more volatility & risk, INKT or TRDA?

Does the media favor INKT or TRDA?

Summary

How does MiNK Therapeutics compare to Forte Biosciences?

Do insiders & institutionals hold more shares of FBRX or INKT?

Do analysts recommend FBRX or INKT?

Which has higher earnings & valuation, FBRX or INKT?

Is FBRX or INKT more profitable?

Which has more volatility & risk, FBRX or INKT?

Does the media prefer FBRX or INKT?

Summary

How does MiNK Therapeutics compare to Akebia Therapeutics?

Is INKT or AKBA more profitable?

Do analysts prefer INKT or AKBA?

Do insiders and institutionals hold more shares of INKT or AKBA?

Which has stronger earnings & valuation, INKT or AKBA?

Does the media favor INKT or AKBA?

Which has more risk & volatility, INKT or AKBA?

Summary

How does MiNK Therapeutics compare to Humacyte?

Which has preferable earnings & valuation, HUMA or INKT?

Does the media refer more to HUMA or INKT?

Do insiders & institutionals hold more shares of HUMA or INKT?

Do analysts rate HUMA or INKT?

Is HUMA or INKT more profitable?

Which has more risk and volatility, HUMA or INKT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INKT vs. The Competition

MiNK Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools